CAI | Ticker Profile - Titan Protect

CAI

Caris Life Sciences, Inc.

Healthcare · Biotechnology · NMS

$16.49

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$4.3B

Total market value of the company

Trailing P/E

N/A

Forward P/E

41.27

Based on estimated future earnings — lower means cheaper

Rev Growth

+78.8%

Year-over-year revenue change

Profit Margin

3.7%

How much profit the company keeps from each dollar of revenue

ROE

28.4%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$28.00

+70% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 13 analysts covering this stock

About Caris Life Sciences, Inc.

Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients. The company was founded in 2008 and is headquartered in Irving, Texas.

https://www.carislifesciences.com

Country: United States Employees: 1,846 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

-0.570

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0560

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.673

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-42.4%

Historical annualised return based on price data

Max Drawdown

-63.0%

Largest peak-to-trough decline — the worst it has been

HMM State

BULL

Statistical model sees bullish momentum

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$42.50

61% below the year high

52W Low

$14.19

16% above the year low

Avg Volume

2,572,222

Average daily shares traded — higher means easier to buy and sell

Short Ratio

4.5

Days it would take all short sellers to cover — higher means more crowded

Short % Float

10.2%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-2.76

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

72.61

Heavy leverage — higher financial risk if revenues decline

Current Ratio

7.05

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

6.35

Like current ratio but excludes inventory — stricter test

Gross Margin

68.9%

Revenue left after cost of goods — higher means pricing power

Operating Margin

2.4%

Profit from core operations before interest and tax

Free Cash Flow

$102M

Positive — the business generates more cash than it spends

Revenue (TTM)

$907M

Total revenue over the last 12 months

Net Income

$-411,424,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$36.00

Target Median

$28.00

Target Low

$21.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go